Longeveron vs ProKidney
LGVN and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LGVN and PROK compare
ProKidney is the larger company, worth 4.9 times as much as Longeveron ($333M against $67.3M).
ProKidney grew revenue faster over the last twelve months (55.2% versus −42.7% for Longeveron).
Longeveron keeps more of each dollar of sales as profit, with a net margin of −1978% compared with −10288% at ProKidney.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LGVN | PROK |
|---|---|---|
| Size and price | ||
| Market cap | $67.3M | $333M |
| Share price | $2.11 | $1.10 |
| Change, 1 year | −69.0% | −54.4% |
| Change, 5 years | −99.9% | −88.9% |
| Beta (5Y) | 1.44 | 1.93 |
| Employees | 37 | 231 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 56.7× (better) | 407× |
| P/B | 6.5× | – |
| FCF yield | −30.5% (better) | −48.0% |
| Growth | ||
| Revenue growth (TTM) | −42.7% | 55.2% (better) |
| Revenue growth, 5Y average | −26.6% | – |
| Profitability | ||
| Gross margin | 69.8% | – |
| Operating margin | −1993% (better) | −21665% |
| Net margin | −1978% (better) | −10288% |
| FCF margin | −1730% (better) | −19527% |
| Return on equity | −204% | – |
| Return on invested capital | −1412% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9327.2× |
| Current ratio | 2.63 | 8.36 (better) |
| Altman Z-score | −9.42 | −1.33 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −7.3% |
| Shareholder yield | 0.00% (better) | −7.3% |
| Ownership | ||
| Held by institutions | 1.5% | 16.1% |
| Held by insiders | 43.8% | 62.9% |
| Insider net buying, 12 months | – | −$1.1M |
| Short interest, % of float | 0.88% | 21.7% |
Go deeper
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
- PROK stock overview
- PROK income statement
- PROK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.